Develops blood tests for early cancer detection.
Jun 2026Revenue $165M/yrExpenses $725M/yr
No trendCash runway ≈ 2 months from Jun 2026
Figures by year
When will GRAIL be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $165M and expenses $725M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $147M | $709M | −$562M |
| Dec 2024 | $126M | $2.31B | −$2.19B |
| Dec 2023 | $93.1M | $1.61B | −$1.52B |
| Jan 2023 | $55.5M | $5.50B | −$5.44B |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.